Procter & Gamble Co. (PG) Falls 2.69% for December 21

Equities Staff |

One of the S&P 500’s big losers for Monday December 21 was Procter & Gamble Co. (PG). The company’s stock fell 2.69% to $78.13 on volume of 21.34 million shares.

The stock opened the day at 79.95 and traded between a low of $78.13 and a high of $80.12. The stock finished the day down $2.16 per share. Procter & Gamble Co. has an average daily volume of 9.98 million and a total float of 2.72 billion shares. The 50-day SMA for Procter & Gamble Co. is $76.17 and its 200-day SMA is $76.69. The high for the stock over the last 52 weeks is $93.89 and the low is $65.02.

Procter & Gamble Co provides consumer packaged goods. It markets its products in about 180 countries through mass merchandisers, grocery stores, membership club stores, drug stores, department stores among others.

Procter & Gamble Co. is centered in Cincinnati, OH, and has 110,000 employees. Today’s trading day leaves the company with a market cap of $212.56 billionwith a P/E Ratio of 29.4. The company has a P/S ratio of 3.01, P/B ratio of 3.47, and a 59.3.

For a complete fundamental analysis analysis of Procter & Gamble Co., check out’s Stock Valuation Analysis report for PG. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…